FIELD: biotechnology.
SUBSTANCE: invention relates to a method for production of antibodies suitable for use in cats that are specifically associated with the cat nerve growth factor (NGF) and neutralise the ability of the cat NGF to contact the cat NGF p75 or TrkA receptor and the corresponding antibodies. To implement this method, a donor antibody is obtained from a species other than a cat, the donor antibody having a binding specificity for the target antigen present in cats. Then, each amino acid residue in the sequence of the framework regions of the donor antibody is compared to each amino acid residue present at the corresponding position in the sequence of the framework regions of cat antibodies pool. Then, the identified amino acid residues in the donor antibody are replaced with the amino acid residues present at the corresponding position in the pool of cat antibodies. The resulting antibody does not contain any amino acid foreign at the corresponding position in cats, at any position within the framework regions. This invention also discloses a pharmaceutical composition and a kit containing the said antibodies for treatment of pain in cats, in particular pain associated with arthritis or osteoarthritis immune-mediated rheumatoid arthritis.
EFFECT: decrease or loss of antigen-binding activity is avoided.
16 cl, 17 dwg, 16 tbl, 11 ex
